Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 1 Neoplasms 1 Motor Activity 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Congenital Abnormalities 1 Cardiovascular Diseases 1 Advanced Cancer 1

Interventions

Nivolumab 20 Ipilimumab 10 Surveys and Questionnaires 7 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Interviews as Topic 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × Health Services Needs and Demand × Clear all

NCT06616298 2026-05-05

ALIGN

University of Colorado, Denver

Phase NA Recruiting

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡